Protection against congenital cytomegalovirus infection and disease in guinea pigs, conferred by a purified recombinant glycoprotein B vaccine

Mark R. Schleiss, Nigel Bourne, Greg Stroup, Fernando J. Bravo, Nancy J. Jensen, David I. Bernstein

Research output: Contribution to journalArticle

76 Citations (Scopus)

Abstract

Glycoprotein B (gB) has emerged as a subunit-vaccine candidate for congenital cytomegalovirus (CMV) infection, a major public health problem. The present study evaluated a cloned, recombinant gB vaccine in the guinea pig cytomegalovirus (GPCMV) model of congenital infection. Guinea pigs were immunized with gB, which was coadministered with either Freund's adjuvant or alum. All gB-immunized dams had enzyme-linked immunosorbent-assay and neutralizing-antibody responses, with significantly higher titers in the gB/Freund's group. Pregnant dams were challenged with GPCMV subcutaneously during the 3rd trimester. Maternal DNAemia on day 10 after infection trended lower in gB-immunized dams than in control animals, with significant reductions in the gB/Freund's group. Vaccination resulted in a highly significant reduction in pup mortality. For the gB-vaccine groups, pup mortality was significantly lower, and reduced rates of GPCMV transmission were noted, for dams immunized with gB and Freund's adjuvant, compared with dams immunized with gB and alum. These are the first data indicating that a recombinant gB vaccine protects against congenital CMV infection and disease.

Original languageEnglish (US)
Pages (from-to)1374-1381
Number of pages8
JournalJournal of Infectious Diseases
Volume189
Issue number8
DOIs
StatePublished - Apr 15 2004
Externally publishedYes

Fingerprint

Cytomegalovirus Infections
Glycoproteins
Guinea Pigs
Vaccines
Roseolovirus
Freund's Adjuvant
Subunit Vaccines
Mortality
Infection
Neutralizing Antibodies
Antibody Formation
Vaccination
Public Health
Enzyme-Linked Immunosorbent Assay
Mothers

ASJC Scopus subject areas

  • Public Health, Environmental and Occupational Health
  • Immunology

Cite this

Protection against congenital cytomegalovirus infection and disease in guinea pigs, conferred by a purified recombinant glycoprotein B vaccine. / Schleiss, Mark R.; Bourne, Nigel; Stroup, Greg; Bravo, Fernando J.; Jensen, Nancy J.; Bernstein, David I.

In: Journal of Infectious Diseases, Vol. 189, No. 8, 15.04.2004, p. 1374-1381.

Research output: Contribution to journalArticle

Schleiss, Mark R. ; Bourne, Nigel ; Stroup, Greg ; Bravo, Fernando J. ; Jensen, Nancy J. ; Bernstein, David I. / Protection against congenital cytomegalovirus infection and disease in guinea pigs, conferred by a purified recombinant glycoprotein B vaccine. In: Journal of Infectious Diseases. 2004 ; Vol. 189, No. 8. pp. 1374-1381.
@article{3a957738846e49f58cda4a2b3238a0fb,
title = "Protection against congenital cytomegalovirus infection and disease in guinea pigs, conferred by a purified recombinant glycoprotein B vaccine",
abstract = "Glycoprotein B (gB) has emerged as a subunit-vaccine candidate for congenital cytomegalovirus (CMV) infection, a major public health problem. The present study evaluated a cloned, recombinant gB vaccine in the guinea pig cytomegalovirus (GPCMV) model of congenital infection. Guinea pigs were immunized with gB, which was coadministered with either Freund's adjuvant or alum. All gB-immunized dams had enzyme-linked immunosorbent-assay and neutralizing-antibody responses, with significantly higher titers in the gB/Freund's group. Pregnant dams were challenged with GPCMV subcutaneously during the 3rd trimester. Maternal DNAemia on day 10 after infection trended lower in gB-immunized dams than in control animals, with significant reductions in the gB/Freund's group. Vaccination resulted in a highly significant reduction in pup mortality. For the gB-vaccine groups, pup mortality was significantly lower, and reduced rates of GPCMV transmission were noted, for dams immunized with gB and Freund's adjuvant, compared with dams immunized with gB and alum. These are the first data indicating that a recombinant gB vaccine protects against congenital CMV infection and disease.",
author = "Schleiss, {Mark R.} and Nigel Bourne and Greg Stroup and Bravo, {Fernando J.} and Jensen, {Nancy J.} and Bernstein, {David I.}",
year = "2004",
month = "4",
day = "15",
doi = "10.1086/382751",
language = "English (US)",
volume = "189",
pages = "1374--1381",
journal = "Journal of Infectious Diseases",
issn = "0022-1899",
publisher = "Oxford University Press",
number = "8",

}

TY - JOUR

T1 - Protection against congenital cytomegalovirus infection and disease in guinea pigs, conferred by a purified recombinant glycoprotein B vaccine

AU - Schleiss, Mark R.

AU - Bourne, Nigel

AU - Stroup, Greg

AU - Bravo, Fernando J.

AU - Jensen, Nancy J.

AU - Bernstein, David I.

PY - 2004/4/15

Y1 - 2004/4/15

N2 - Glycoprotein B (gB) has emerged as a subunit-vaccine candidate for congenital cytomegalovirus (CMV) infection, a major public health problem. The present study evaluated a cloned, recombinant gB vaccine in the guinea pig cytomegalovirus (GPCMV) model of congenital infection. Guinea pigs were immunized with gB, which was coadministered with either Freund's adjuvant or alum. All gB-immunized dams had enzyme-linked immunosorbent-assay and neutralizing-antibody responses, with significantly higher titers in the gB/Freund's group. Pregnant dams were challenged with GPCMV subcutaneously during the 3rd trimester. Maternal DNAemia on day 10 after infection trended lower in gB-immunized dams than in control animals, with significant reductions in the gB/Freund's group. Vaccination resulted in a highly significant reduction in pup mortality. For the gB-vaccine groups, pup mortality was significantly lower, and reduced rates of GPCMV transmission were noted, for dams immunized with gB and Freund's adjuvant, compared with dams immunized with gB and alum. These are the first data indicating that a recombinant gB vaccine protects against congenital CMV infection and disease.

AB - Glycoprotein B (gB) has emerged as a subunit-vaccine candidate for congenital cytomegalovirus (CMV) infection, a major public health problem. The present study evaluated a cloned, recombinant gB vaccine in the guinea pig cytomegalovirus (GPCMV) model of congenital infection. Guinea pigs were immunized with gB, which was coadministered with either Freund's adjuvant or alum. All gB-immunized dams had enzyme-linked immunosorbent-assay and neutralizing-antibody responses, with significantly higher titers in the gB/Freund's group. Pregnant dams were challenged with GPCMV subcutaneously during the 3rd trimester. Maternal DNAemia on day 10 after infection trended lower in gB-immunized dams than in control animals, with significant reductions in the gB/Freund's group. Vaccination resulted in a highly significant reduction in pup mortality. For the gB-vaccine groups, pup mortality was significantly lower, and reduced rates of GPCMV transmission were noted, for dams immunized with gB and Freund's adjuvant, compared with dams immunized with gB and alum. These are the first data indicating that a recombinant gB vaccine protects against congenital CMV infection and disease.

UR - http://www.scopus.com/inward/record.url?scp=2142705176&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=2142705176&partnerID=8YFLogxK

U2 - 10.1086/382751

DO - 10.1086/382751

M3 - Article

VL - 189

SP - 1374

EP - 1381

JO - Journal of Infectious Diseases

JF - Journal of Infectious Diseases

SN - 0022-1899

IS - 8

ER -